INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Iovance Biotherapeutics, Inc. (IOVA) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Group 1 - A shareholder class action lawsuit has been filed against Iovance Biotherapeutics, alleging materially false and misleading statements regarding the company's business and operations [1] - The lawsuit claims that new Authorized Treatment Centers (ATCs) are facing longer timelines to begin treating patients with Amtagvi, which has led to inefficiencies in patient identification and selection [1] - These dynamics have resulted in higher costs and lower revenue for Iovance, as ATCs are unable to keep pace with the manufactured product [1] Group 2 - Shareholders who purchased Iovance shares between May 9, 2024, and May 8, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request appointment as lead plaintiff in the case is July 14, 2025 [3] - Holzer & Holzer, LLC is a law firm specializing in securities litigation and has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]